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Background: Antiviral treatment with nucleoside analogs has been used for chronic hep-
atitis B (CHB). each kind of nucleoside analog has its own characteristics and suitability 
for patients. Telbivudine (LdT, brand name: Sebivo, Beijing novartis pharma Ltd) is the 
newest nucleoside analog, with strong and rapid viral suppression. However, its resist-
ance rate is relatively high during long-term application, due to low genetic barriers to 
resistance. So, it is necessary to increase the effect and reduce resistance with effective 
management, according to baseline factors and early on-treatment responses.
Objectives: To reveal possible predictive factors of the effect of telbivudine (LdT) treat-
ment on naïve HBeAg-positive chronic hepatitis B (CHB) patients to optimize treatment.
Patients and Methods: A total 71 naïve chronic hepatitis B (CHB) patients who met the in-
clusion criteria were enrolled. All patients were treated with LdT 600 mg Qd for at least 
52 weeks. Multiple logistic regression analyses were done to investigate the predictive 
values of baseline factors and responses at Week 24. 
Results: The reduction in hepatitis virus B (HBV) DnA level was 6.44 ± 2.38 lg copies/mL 
at Week 52 compared with baseline. The complete virus response (CVR), biochemical 
response (BR), serological response (SR), and drug resistance (DR) were 61.99%, 77.46%, 
35.21%, and 8.45% respectively. By multiple regression analysis, baseline alanine ami-
notransferase (ALT) levels significantly affected CVR (P = 0.024, oR = 1.008), and baseline 
ALT and baseline HBV DnA levels were independent compact factors of SR (P = 0.012, oR 
= 1.007; P = 0.001, oR = 0.423). The differences in CVR, SR, and DR in patients with ALT > 
120 Iu/mL compared with patients with ALT ≤ 120 Iu/mL were statistically significant. The 
differences in SR in patients with HBV DnA > 107 copies/mL compared with patients with 
HBV DnA ≤ 107 copies/mL were statistically significant. Additionally, CVR, BR, and SR were 
differed significantly between patients with HBV DnA lower than 300 copies/mL at Week 
24 and patients with HBV DnA higher than 300 copies/mL (P = 0.000, P = 0.0016, and P = 
0.000, respectively). 
Conclusions: There were more responders among naïve HBeAg-positive chronic hepatitis 
B patients with lower HBV DnA levels (especially lower than 107 copies/mL) and higher 
ALT values (especially higher than 120 Iu/mL at baseline) to LdT treatment. Adjustments 
for treatment strategy should be considered if HBV DnA > 300 copies/mL at Week 24 is 
observed. 
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 Implication for health policy/practice/research/medical education:
Instead of focusing on the curative effect of telbivudine for hepatitis b virus, this study is aimed to explore predictive elements for 
52 weeks’ telbivudine treatment on naïve HBeAg positive chronic hepatitis B,mainly including baseline factors and viral response 
during therapy,so as to identify the characteristics of patients who may have better effect and lower drug resistance to telbivudine 
treatment, and to optimize anti-viral therapy.
1. Background
In recent years, much evidence has confirmed that 
antiviral treatment with nucleoside analogs of chronic 
hepatitis B (CHB) can inhibit viral replication, improve 
liver function, and reduce the incidence of decompen-
sated liver diseases, including cirrhosis and liver can-
cer, and thus improve the prognosis of diseases. Each 
kind  of  nucleoside  analog  has  its  own  characteristics 
and suitability for patients. So, it is necessary to find out 
the characteristics and impact factor of each medicine 
to improve its clinical application. of the four available 
nucleoside analogs in China (1), telbivudine (LdT, brand 
name: Sebivo, Beijing novartis pharma Ltd) is the newest 
nucleoside analog, with strong and rapid viral suppres-
sion. However, its resistance rate is relatively high dur-
ing its long-term application, due to low genetic barriers 
to resistance (2). According to the results of the Global 
study, the effects can be increased and the resistance rate 
can be reduced with effective management according to 
baseline factors and early on-treatment responses (3).
2. Objectives
In this study, a total of 71 naïve HBeAg-positive CHB pa-
tients who received LdT monotherapy for 52 weeks were 
enrolled,  and  impact  factors  on  effect  and  resistance 
were analyzed. We wished to identify the possible pre-
dictive factors of the effect of LdT treatment on naïve 
HBeAg-positive CHB patients to optimized the applica-
tion of LdT.
3. Patients and Methods
3.1. Patients and Study Design
patients who visited the outpatient clinic of West China 
Hospital of Sichuan University from March 2008 to Au-
gust 2009 and met the inclusion criteria were enrolled in 
this study. The inclusion criteria were as follows: positiv-
ity for hepatitis B surface antigen (HBsAg) and hepatitis 
B e antigen (HbeAg) for at least 6 months and without 
history of antiviral therapy with nucleoside analogs; ala-
nine aminotransferase (ALT) levels between 2 to 10 times 
the  upper  normal  levels  (UnL);  and  hepatitis  virus  B 
(HBV) DnA levels ≥ 105 copies/mL. patients were excluded 
if they were coinfected with human immunodeficiency 
virus (HIV) or other hepatitis viruses (hepatitis virus A, 
hepatitis virus C, hepatitis virus E, and hepatitis virus 
D) or had nonalcoholic fatty liver disease (nAFLD), alco-
holic liver disease, posthepatitic cirrhosis, or hepatocel-
lular carcinoma. The diagnosis of fatty liver depended 
on the characteristic rise in liver enzymes, including 
γ-glutamyltransferase; change in ultrasound Doppler; 
and other underlying diseases with metabolic disorder. 
The diagnosis of alcoholic liver disease depended on al-
cohol consumption, history of alcohol use, and a special 
imaging  examination,  including  ultrasound  Doppler 
and  computed  tomography.  Liver  cirrhosis  was  con-
firmed through invasive and noninvasive techniques, 
including liver stiffness measurement, special imaging 
examination, and liver biopsy. Hepatocellular carcinoma 
was diagnosed by elevated A fetal protein (AFp) and char-
acteristic imaging manifestation, including computed 
tomography (CT) and magnetic resonance imaging 
(MRI). After patients signed an informed consent form, 
they were given LdT 600 mg daily as antiviral treatment 
for at least 52 weeks. During the treatment period, pa-
tients were not given any other antiviral drugs or medi-
cines to protect liver function.
3.2. Serum Assays
Analyses of liver and renal functions, which included 
serum levels of total bilirubin (TB), ALT, albumin (ALB), 
blood urea nitrogen (BUn), blood creatinine (Cr), amy-
lase, and lipase, were performed at baseline and at Weeks 
12, 24, 36, and 52 of LdT treatment using an automatic 
biochemistry analyzer (olympus AU5400, olympus Cor-
poration, Tokyo, Japan). The status of HBsAg, HBeAg, and 
antibodies to HBeAg (anti-HBe) was measured by mic-
roparticle enzyme-linked immunosorbent assay (eLISA) 
at baseline and Weeks 24 and 52. Serum HBV DnA was 
quantified by Cobas TaqMan Real-Time polymerase Chain 
Reaction (PCR) Assay (Roche Diagnostics) (the sensitiv-
ity level was 70 copies/mL and the maximum valid level 
was 109 copies/mL) at baseline and Weeks 12, 24, 36, and 
52, with a linear range between 300 and 109 copies/mL. 
LdT-associated  mutations  were  assessed  via  direct  se-
quencing if virological breakthrough occurred during 
the treatment. All assays were performed in the micro-
biological laboratories of West China Hospital, Sichuan 
University.
3.3. Definition and Evaluation of Efficacy
Virological response (VR) was defined as the level of 
decline at the end of treatment. A complete virological 
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levels to less than the level of detection (< 300 copies/
mL).  Biochemical  response  (BR)  was  defined  as  a  nor-
malization of ALT levels. Serological response (SR) was 
defined as disappearance of HBeAg with or without the 
appearance of hepatitis B e antibody (HbeAb). Virologi-
cal breakthrough was defined as an increase in serum 
HBV DnA > 1 log copy/mL compared to the on-treatment 
nadir that was confirmed in two consecutive tests. Drug 
resistance (DR) was defined as the emergence of virologi-
cal breakthrough and the presence of drug-resistant mu-
tations. The curative effect of LdT was assessed at Weeks 
12, 24, and 52 during treatment. Rates of CVR, BR, SR, and 
DR were assessed at the time points above respectively. 
Baseline factors, including age, gender, ALT, and DnA lev-
els, were analyzed for their effects on LdT treatment. HBV 
DnA levels at Week 24 were analyzed as impact factors 
during the treatment 
3.4. Statistical Analysis
Quantitative data were presented as the mean ± stan-
dard deviation (SD), categorical data were presented as 
counts and percentages, and HBV DnA levels were pre-
sented as log-transformation. Data were analyzed using 
SpSS, version 13.0 (SpSS Inc., Chicago, IL). AnoVA was used 
to analyze the reduction in HBV DnA levels at Weeks 12, 
24, and 52 respectively. pearson chi-square was used to 
compare CVR, BR, SR, and DR at Week 52 between pa-
tients with different baseline factors. Logistic regression 
analysis was used to investigate the baseline predictors 
for the response to treatment. Age, baseline DnA, and 
baseline  ALT  were  quantitative  variables.  Gender  was 
the qualitative variable. In all cases, tests of significance 
were 2-tailed, and statistical significance was defined as 
P < 0.05.
4. Results
4.1. General Information
A  total  of  71  patients  were  included,  comprising  60 
(84.5%) males and 11 (15.5%) females, with ages ranging 
from 17 to 46 years (mean 28 ± 8.337). Baseline data were 
as follows: the median level of HBV DnA was 1.25 ×108 cop-
ies/mL, and the mean ALT level was 183.99 ± 131.87 IU/mL.
4.2. Virological Eﬀect
The reduction in HBV DnA levels was 4.71 ± 1.88, 5.84 ± 
2.04, and 6.44 ± 2.38 lg copies/mL at Weeks 12, 24, and 52 
respectively, compared with baseline (Figure 1). The dif-
ference in the magnitude of the decrease was statisti-
cally significant at the three time points (F = 12.294, P = 
0.000). The prevalence of HBV DnA level < 300 copies/
mL was 25.35% (18/71), 45.07% (32/71), and 61.97% (44/71) at 
Weeks 12, 24, and 52, respectively. 
4.3. Biochemical Eﬀect
ALT  normalization  was  achieved  in  39.44%  (28/71), 
64.79% (46/71), and 77.46% (55/71) of patients at Weeks 12, 
24, and 52, respectively. 
4.4 . Serological Eﬀect
The  disappearance  of  HBeAg  was  observed  in  21.13% 
(15/71), 28.17% (20/71), and 35.21% (25/71) of patients at 
Weeks 12, 24, and 52, respectively. HBeAg/Anti-HBe sero-
conversion was achieved in 9.86% (7/71), 16.90% (12/71) and 
23.94% (17/71) of patients at Weeks 12, 24, and 52, respec-
tively.
Figure 1. Reduction of HBV DnA Level at Weeks 12, 24 and 52 Respectively 
Compared With That of the Baseline
4.5. Resistance and Side Eﬀects
By Week 52, viral breakthrough occurred in 7 (9.86%) 
patients, 6 of which (8.45%) had confirmed genotypic re-
sistance, comprising 5 cases with rtM204I and 1 case with 
rtLl80M + rtM204V. 
overall,  LdT  demonstrated  a  good  safety  profile.  All 
levels of serum electrolytes were normal. Mild adverse 
reactions were observed in 4 (5.63%) patients, 3 of whom 
had a mild to moderate increase in blood creatine ki-
nase without myalgia or muscle weakness at Week 
24, 36, and 36, respectively. In the follow-up period, 
increased creatine kinase all reduced in the next 
3 to 6 months without special treatment or drug 
withdrawal. Another patient suffered from insomnia, 
which  disappeared  after  symptomatic  treatment.  no 
renal failure or pancreatitis occurred in any patient.
4.6. Logistic Regression Analysis of Baseline Impact Fac-
tors for Antiviral Eﬀect of LdT
As shown in Table 1, when CVR at Week 52 was regarded 
as the outcome variable, the multiple logistic regression 
analyses of compact factors at baseline showed that only 
baseline ALT level (P = 0.024) was an independent com-
pact factor of Week 52 CVR. Based on the odds ratio (oR 
= 1.008), it was easier to achieve undetectable HBV DnA 
levels at Week 52 in patients with higher ALT levels com-
pared with patients with lower ALT levels at baseline. If 
BR at Week 52 was regarded as the outcome variable, the 
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at baseline showed no impact of BR. When SR at Week 52 
was regarded as the outcome variable, the multiple lo-
gistic regression analyses of compact factors at baseline 
showed that baseline ALT level (P = 0.012) and baseline 
HBV DnA level (P = 0.001) were both independent com-
pact factors of Week 52 SR. The odds ratio (oR = 1.007 and 
0.423) showed that it was easier to achieve HBeAg disap-
pearance at Week 52 in patients with higher ALT levels 
and lower HBV DnA levels compared with patients with 
lower ALT levels and higher HBV DnA levels at baseline. 
When DR at week 52 was regarded as the outcome vari-
able, the multiple logistic regression analyses of com-
pact factors at baseline showed no impact of DR.
P value Adjusted OR a OR a (95% CI a)
CVRa
Age b
Gender c
Baseline DnA a, b
Baseline ALT a, b
0.666
0.075
0.231
0.024
1.381
0.420
0.671
1.008
0.319–5.983
0.153–1.062
0.635–1.365
1.001–1.015
BR a
Age
Gender
Baseline DnA
Baseline ALT
0.481
0.213
0.459
0.161
0.972
0.252
0.817
0.995
0.899–1.051
0.029–2.207
0.490–2.771
0.988–1.002
SR a
Age
Gender
Baseline DnA
Baseline ALT
0.300
0.172
0.001
0.012
0.964
2.914
0.423
1.007
0.899-1.033
0.628-13.517
0.252-0.711
1.001-1.012
DRa
Age
Gender
Baseline DnA
Baseline ALT
0.589
0.119
0.104
0.230
0.965
7.237
1.000
1.008
0.848–1.098
0.600–87.286
0.999–1.001
0.981–1.005
Table 1. Logistic Regression Analyses With CVR, BR, SR and DR at week 52 
as outcome Variable
a  Abbreviations: ALT, alanine aminotransferase; BR, biochemical re-
sponse; CI, confidence interval; CVR, complete virus response; DnA, de-
oxyribose nucleic acid; DR, Drug resistance; oR, odds ratio; SR, serologi-
cal response
b Age, baseline DnA and baseline ALT are quantitative variables
c Gender is qualitative variable
4.7 Comparison of CVR, BR, SR, and DR at Week 52 Be-
tween Patients With Baseline ALT > 120 IU/mL and ≤ 120 
IU/mL 
All patients were divided into two groups: baseline ALT 
> 120 Iu/mL and ≤ 120 Iu/mL. At Week 52, the CVR, BR, SR, 
and DR of 41 patients with baseline ALT > 120 Iu/mL were 
73.2% (30/41), 85.4% (35/41), 46.3% (19/41), and 2.4% (1/41), 
respectively. In the 30 patients with baseline ALT ≤ 120 
Iu/mL, the CVR, BR, SR, and DR were 46.7% (14/30), 66.7% 
(20/30), 20.0% (6/30), and 16.7% (5/30), respectively. The 
differences in CVR, SR, and DR between the two groups 
were  statistically  significant  (X2 = 5.164, P =0.023; X2 = 
5.269, P = 0.022; X2 = 4.533, P = 0.033). no significant differ-
ence was found in BR between the two groups (X2 = 3.470, 
P = 0.062) (Figure 2).
4.8. Comparison of CVR, BR, SR, and DR Between Pa-
tients With Baseline HBV DNA > 107 copies/mL and HBV 
DNA ≤ 107 copies/mL 
All  patients  were  divided  into  two  groups:  baseline 
HBV DnA > 107 copies/mL and ≤ 107 copies/mL. At Week 
52, the CVR, BR, SR, and DR of 54 patients with baseline 
HBV DnA > 107 copies/mL were 59.3% (32/54), 77.8% (42/54), 
27.8% (15/54), and 5.6% (3/54), respectively. In the 17 pa-
tients with HBV DnA ≤ 107 copies/ml, the CVR, BR, SR, and 
DR were 70.6% (12/17), 76.5% (13/17), 58.8% (10/17), and 17.6% 
(3/17), respectively. The differences in SR between the two 
groups were statistically significant (X2 = 5.463, P = 0.019). 
no significant difference was found in CVR, BR, or DR be-
tween the two groups (X2 = 0.704, P=0.401; X2 = 0.013, P = 
0.910; X2 = 2.443, P = 0.118) (Figure 3).
4.9. The Rate of HBV DNA < 300 copies/mL at Weeks 24 
as a Predictive Factor of Efficacy During Treatment of 
Week 52
For 32 patients with HBV DnA < 300 copies/mL at Week 
24, the CVR, BR, SR, and DR at week 52 were 90.63% (29/32), 
90.63% (29/32), 62.50% (20/32), and 6.25% (2/32), respec-
tively. But, for the other 39 patients with HBV DnA ≥ 300 
copies/mL at Week 24, the CVR, BR, SR, and DR at Week 
52 were 38.46% (15/39), 66.67% (26/39), 12.82% (5/39), and 
10.26% (4/39), respectively. The differences in CVR, BR, and 
SR between the two groups were statistically significant 
(X2 = 20.295, P = 0.000; X2 = 5.780, P = 0.0016; X2 = 19.016, P = 
0.000). But, the difference in DR between the two groups 
was not statistically significant (X2 = 0.365, P = 0.546) (Fig-
ure 4).
5. Discussion
The importance of optimizing therapy with nucleoside 
analogs lies in their long-term treatment course and in-
evitable resistance (3). How to screen patients who are 
the  most  qualified  targets  for  certain  drugs  is  widely 
debated. During therapy, efficacy predictions are usually 
made to achieve the best effect, the lowest occurrence 
Figure 2. Comparison of CVR, BR, SR and DR at Week 52 Between patients 
With Baseline ALT > 120IU/mL and Those With ≤ 120 IU/mL. 
CVR, complete virological response; BR, biochemical response; SR, sero-
logical response; DR, durg resistance984 Eﬀect and Predictive Elements for LdT Therapy on CHB Zhu XF et al.
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Figure 3. Comparison of CVR, BR, SR and DR at Week 52 Between patients With 
Baseline HBV DnA > 107 Copies/mL and Those With HBV DnA ≤ 10 7 Copies/mL
CVR, complete virological response; BR, biochemical response; SR, sero-
logical response; DR, durg resistance
Figure 4. The Rate of HBV DnA < 300 Copies/mL at Weeks 24 as predictive 
Factor During Treatment for efficacy of Week 52
CVR, complete virological response; BR, biochemical response; SR, sero-
logical response
of resistance, and the highest effect:cost ratio. In recent 
years, optimization therapy with nucleoside analogs has 
focused on the baseline situation, considering early re-
sponse and the application of roadmaps (4). Due to its 
potent antiviral effect (5), relatively higher seroconver-
sion rate of HBeAg and HbeAb (6), and affordable price, 
LdT is still widely used as the first option in naive CHB 
patients, especially for HBeAg-positive patients in certain 
countries, including China and other countries of Asia. 
Therefore, research on the predictive factors of antiviral 
efficacy of LdT is still important and can provide us with 
better evidence for optimization therapy. In this study, 71 
CHB patients who received at least 52 weeks of LdT treat-
ment were included. The CVR, BR, and SR were 61.97%, 
77.46%, and 35.21% after 52 weeks of treatment, respec-
tively. At the same time, the DR was 8.45% at Week 52. The 
type of gene mutation was mainly rtM204I. Another type 
was the rtLl80M + rtM204V alliance mutation. These 
results are consistent with other published data (7, 8).
This study investigated several baseline host and viral 
factors that may influence antiviral efficacy, including 
age, gender, and baseline HBV DnA and ALT levels. The 
multiple regression statistical analyses showed that pa-
tient age and gender had no impact on CVR, BR, SR, or 
DR. Baseline ALT level significantly affected CVR, suggest-
ing that higher ALT levels lead to a higher CVR, similar to 
results of the GLoBe clinical trial (9) and other reports 
(10, 11). Some scholars have proposed that better effects 
of LdT could be obtained in HBeAg-positive CHB patients 
with 10 to 20 times the upper limit of normal (12). Fur-
ther, the occurrence of SR correlates significantly with 
baseline  HBV  DnA  and  ALT  levels,  suggesting  that  pa-
tients with higher ALT and lower HBV DnA levels at base-
line achieve E-antigen disappearance or seroconversion 
more easily, consistent with other reports11. At the same 
time, no baseline factor had an impact on BR or DR, per-
haps due to too few cases with resistance for DR, unsuit-
able for statistical analysis. We tried to identify HBeAg-
positive CHB patients who were most appropriate for Ldt 
treatment at baseline. ALT values and HBV DnA were ana-
lyzed and compared. The differences in CVR, SR, and DR 
between patients with baseline ALT > 120 IU/mL and ALT 
≤ 120 Iu/ml were statistically significant, and the differ-
ences in SR between patients with baseline HBV DnA lev-
el > 107 copies/mL and ≤ 107 copies/mL were statistically 
significant, suggesting that patients with ALT > 120 and 
HBV DnA ≤ 107 copies/mL at baseline are more suitable 
for LdT therapy, similar to another report (13).
The optimization strategy  also includes medication 
adjustments according to early response during treat-
ment, except according to baseline factor (14). For differ-
ent drugs, alterations should be made at different time 
points  due  differing  characteristics  (15).  The  roadmap 
concept  was  proposed  according  to  the  results  of  the 
Ldt GLoBe trial (8). It was confirmed that patients with 
undetectable serum HBV DnA levels after 24 weeks had 
the  best  long-term  outcomes,  while  those  with  levels 
remaining above 10,000 copies per ml were unlikely to 
benefit from long-term therapy (16). In this study, the re-
sults showed that the differences in CVR, BR, and SR at 52 
weeks was statistically significant between patients with 
HBV DnA < 300 copies/mL at Week 24 and those HBV DnA 
≥ 300 copies/mL. HBV DnA < 300 copies/mL at Week 24 
had good predictive value for CVR, BR, and SR at Week 52. 
A longer-term study was performed to show that Week 12 
HBV DnA < 200 IU/mL was predictive of a greater chance 
of HBV DnA undetectability and a lower chance of resis-
tance by Year 3. Undetectable HBV DnA at Week 24 was 
predictive of viral suppression at Year 2 but not at Year 
3 (17). The observation period of this study lasted only 1 
year, and it is worth examining in an extended treatment 
course.
of the 71 cases in this study, drug resistance occurred 
in 6 patients (8.45%). However, the observation period 
lasted only 52 weeks. With an extension of the treatment 
course, the occurrence of drug resistance may increase 
gradually. Therefore, it is necessary to monitor the oc-
currence  of  drug  resistance  with  ongoing  treatment. 
Usually, Ldt is regarded as a safe medicine, even for preg-
nant woman (18). In this study, good safety was also con-
firmed. The adverse effects rate was only 5.63%, which 
were reversible, and it was not necessary to interrupt 985 Eﬀect and Predictive Elements for LdT Therapy on CHB Zhu XF et al.
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antiviral therapy. The rate was lower than reported (19). 
In this study, virological effect, biochemical effect, and 
serological  effects  were  used  to  value  clinical  efficacy. 
Histology remains the most exact and reliable index to value 
antiviral eﬀects, but unfortunately, histological informa-
tion and data were unavailable for our patients. This is a 
limitation of our study.
In  summary,  our  results  suggest  the  following  con-
clusions: LdT has good efficacy in naïve HBeAg-positive 
chronic hepatitis B patients, with a good safety profile. In 
particular, there were more responders among patients 
with lower HBV DnA levels, especially less than 107 cop-
ies/ml, and higher ALT values, especially higher than 120 
Iu/ml at baseline, to LdT therapy. At the same time, it is 
crucial to focus on the response at Week 24 during the 
course of treatment. If HBV DnA level is still > 300 copies/
mL at Week 24, alterations or adjustments to the treat-
ment strategy should be considered. The primary limi-
tations of this study are the relatively short observation 
time period and the small number of patients. However, 
the results of this study suggest some clues and indica-
tors of clinical value in the 52-week observation period. It 
is worth performing further studies by continuing treat-
ment for longer terms.
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